LXRX - LEXICON PHARMACEUTICALS, INC.

QQQ $ 624.95 $ 0.00 (0 %)

DIA $ 480.46 $ 0.00 (0 %)

SPY $ 685.02 $ 0.00 (0 %)

TLT $ 89.83 $ 0.00 (0 %)

GLD $ 380.44 $ 0.00 (0 %)

Previous Close

$ 1.56

Open

$ 1.39

Bid

$ 1.49 x 1,150

Ask

$ 1.59 x 950

Day's Range

-- - --

52 Week Range

$ 0.28 - $ 1.66

Volume

3,637,074

Average Volume

Market Cap

566.9M

Beta (5Y Monthly)

$ 1.70

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-14-2025	03-31-2025	10-Q
4	03-07-2025	01-01-1970	10-K
5	11-13-2024	09-30-2024	10-Q
6	08-02-2024	06-30-2024	10-Q
7	05-02-2024	03-31-2024	10-Q
8	03-25-2024	12-31-2023	10-K
9	11-08-2023	09-30-2023	10-Q
10	08-04-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	03-03-2023	12-31-2022	10-K
13	11-09-2022	09-30-2022	10-Q
14	08-03-2022	06-30-2022	10-Q
15	05-05-2022	03-31-2022	10-Q
16	03-10-2022	12-31-2021	10-K
17	11-09-2021	09-30-2021	10-Q
18	08-06-2021	06-30-2021	10-Q
19	05-06-2021	03-31-2021	10-Q
20	03-12-2021	12-31-2020	10-K
21	10-30-2020	09-30-2020	10-Q
22	07-29-2020	06-30-2020	10-Q
23	04-27-2020	03-31-2020	10-Q
24	03-12-2020	12-31-2019	10-K
25	11-07-2019	09-30-2019	10-Q
26	08-01-2019	06-30-2019	10-Q
27	05-01-2019	03-31-2019	10-Q
28	03-15-2019	12-31-2018	10-K
29	11-01-2018	09-30-2018	10-Q
30	07-30-2018	06-30-2018	10-Q
31	05-03-2018	03-31-2018	10-Q
32	03-01-2018	12-31-2017	10-K
33	11-08-2017	09-30-2017	10-Q
34	08-01-2017	06-30-2017	10-Q
35	05-04-2017	03-31-2017	10-Q
36	03-06-2017	12-31-2016	10-K
37	11-07-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	03-11-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Reported Saturday, Lexicon Pharmaceuticals...
11/10/2025 09:00:14

Lexicon Pharmaceuticals Q3 EPS $(0.04) Bea...
11/06/2025 12:31:11

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate ...

Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

Lexicon Pharmaceuticals To Present Data Fr...
11/04/2025 13:34:22

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented d...

Lexicon Pharma Presents Additional Clinica...
10/14/2025 12:02:14

– Results support advancement of 10 mg dose into Phase 3 development –– End-of-Phase 2 meeting request accepted by U.S. FDA; pa...

inventiva-moonlake-immunotherapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Inventiva, MoonLake Immunotherapeutics And...
09/29/2025 12:06:27

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiv...

Lexicon Pharma Updates Zynquista NDA Resub...
09/22/2025 20:02:38

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the Decem...

Lexicon Reports Phase 2b Results For Pilav...
09/17/2025 11:11:34

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the presentation of clinical data from the company's Phase 2b P...

Lexicon Pharma Presents Clinical Data For ...
09/11/2025 12:33:13

Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic per...

Lexicon Pharmaceuticals Submits New Clinic...
09/08/2025 12:43:13

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the Decem...

Lexicon Pharmaceuticals Announces It Will ...
09/04/2025 12:36:49

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Company will present new data demonstrating the reduction ...

HC Wainwright & Co. Reiterates Buy on Lexi...
09/02/2025 16:09:39

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...

Lexicon Pharma Presents Post-Hoc Analysis ...
09/02/2025 12:34:55

Citigroup Maintains Buy on Lexicon Pharmac...
08/07/2025 22:49:27

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target f...

Lexicon Pharmaceuticals Q2 EPS $0.01 Beats...
08/06/2025 11:41:28

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate ...

Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

Lexicon Pharmaceuticals Announces It Has R...
07/31/2025 12:08:33

Lexicon Pharmaceuticals To Present New Dat...
07/18/2025 12:02:59

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from a study of patients describing the impact of diabeti...

Lexicon Pharmaceuticals Received Notice Of...
07/03/2025 13:14:35

https://www.sec.gov/ix?doc=/Archives/edgar/data/1062822/000106282225000035/lxrx-20250703.htm

HC Wainwright & Co. Reiterates Buy on Lexi...
06/24/2025 11:44:18

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $...